Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Guaranteed Paid Placement
    • Cision Media Monitoring
    • Multichannel Amplification
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • All Multimedia

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Accessories
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High-Tech Security
      • Internet Technology
      • Nanotechnology
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Projections or Forecasts
      • Financing Agreements
      • Insurance
      • Investment Options
      • Joint Ventures
      • Mutual Funds
      • Offerings
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing/marketing agreements
      • New Products & Services
      • Obituary
      • Outsourcing Businesses
      • Overseas Real Estate (Non-US)
      • Personnel Announcements
      • Residential Real Estate
      • Small-Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Accessories
      • Computer Electronics
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Design Automation
      • Financial Technology
      • Mobile Devices/Apps
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Natural Gas Utilities
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Computer Accessories
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Computer Accessories
      • Computer Networks
      • Mobile Devices/Apps
      • Telecommunications
      • Telecommunications Carriers & Services
      • Telecommunications Equipment
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wine & Spirits
      • Beverages
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infectious Disease Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental Products & Services
      • European Government
      • Natural Disasters
      • Not-for-Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Children-related news
      • Disabled Persons
      • Diversity, Equity & Inclusion
      • Hispanic-oriented news
      • LGBTQ+
      • Religion
      • Senior Citizens
      • Veterans
      • Women-Related news
      • View All People & Culture

  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Multichannel Amplification
  • All Products
  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring Home
  • Send a Release
    • Chat

    • ALL CONTACT INFO
    • Contact Us


  • News Releases
  • Send a Release
  • Data Privacy
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • News Releases
  • Send a Release
  • Data Privacy
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Cision IR
  • SocialBoost
  • All Products
  • News Releases
  • Send a Release
  • Data Privacy
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • News Releases
  • Send a Release
  • Data Privacy

Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
  • USA - English


News provided by

Infinitopes

09 May, 2024, 15:30 CST

Share this article

Share toX

Share this article

Share toX

Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic

OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the publication of a peer-reviewed article in Human Vaccines & Immunotherapeutics (HVI). The article outlines the current cancer vaccine landscape and the challenges facing vaccine technologies for the treatment of solid tumours to explain the advantages of Infinitopes' combined approach to cancer vaccines: incorporating the right targets and the right vectors, for the right patients at the right time.

The review, entitled "Unlocking Cancer Vaccine Potential: What are the Key Factors?", was an invited contribution from the editorial team at HVI for inclusion in their special edition on cancer vaccines. The Company co-authored the review in close collaboration with senior academics from the University of Oxford's cancer vaccine programme. The article describes the history of cancer vaccine development, the impact of the SARS-CoV-2 pandemic on vaccine immunology, and the hurdles that face the successful clinical development of vaccines within the solid tumour space.

Limited understanding of tumour biology has historically been a major obstacle to progress in cancer vaccine development. Following the announcement of its £12.8m seed funding round in April 2024, Infinitopes is investing in world-leading mass spectrometry equipment to accurately identify the best synergistic tumour targets. This will enable the company to expand the development of its precision-targeted cancer vaccines for five further cancers beyond its lead candidate, which is due to begin phase I/IIa later this year.

Dr Jonathan Kwok, Infinitopes CEO, commented: "Infinitopes' team has amassed an enormous wealth of insight into the fundamental immunology required to develop effective cancer vaccines. Over the past decade, we have crystallised our understanding of the building blocks necessary to design precision-targeted, durably stimulating, affordable vaccine therapies. It's an honour to be invited to share our learnings with readers of the prestigious Human Vaccines & Immunotherapeutics journal, and we look forward to the future collaborations this will unlock."

Lead author Dr Michael Grant, Executive Medical Director of Infinitopes, commented: "The global burden of cancer is increasing, whilst advances in diagnosis and shifts in lifestyle factors are changing the demographics of patients that we see in clinic. There is a growing need for cost-effective treatments that can be deployed in the earlier stages of disease. Cancer vaccines offer a potential solution to this and, in the past few years alone, we have begun to see some exciting results from different vaccine platforms. However, it is vital that we learn from previous failures – as well as recent successes – to optimise the clinical development of future cancer vaccines."

Professor Mark Middleton, Head of the Department of Oncology at the University of Oxford and Scientific Advisory Board member for Infinitopes, added: "As we detect cancers earlier, we need treatments that are cheaper and better tolerated than existing drugs, and cancer vaccines look very promising. Recent trial results show that they work, and they are relatively cheap to make at scale. The challenge now is to understand the rules that govern vaccine activity, so we can give them to the right patients at the right time."

"Unlocking Cancer Vaccine Potential: What are the Key Factors?" is available to read online at:

https://www.tandfonline.com/doi/10.1080/21645515.2024.2331486

Notes to editors

About Infinitopes

Infinitopes Ltd is a soon to be clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford. The Company combines two world leading platforms, in precision antigen discovery and in high efficiency, vector delivery systems, to develop immunologically durable vaccines for use against multiple solid tumour indications. The lead vaccine candidate is expected to begin phase I/IIa trials in Q3 2024. Infinitopes has cultivated in-house talent across antigen discovery, immunology, vaccinology, oncology, biomanufacturing, trials and regulation, winning an 'Innovative Licensing and Access Pathway' (ILAP) innovation passport from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. Infinitopes has also won two prestigious, maximum size nondilutive awards from Innovate UK, a Cancer Therapeutics Award (in 2022) and a Future Economy Investor Partnership (in 2023). In 2024, the company closed its £12.8 m seed financing. Since incorporation, the Infinitopes team has grown from three co-founders to 28 full time equivalents, and is now the largest tenant of Oxford University's BioEscalator Innovation Building. For more information, visit www.infinitopes.com

SOURCE Infinitopes

Modal title

Also from this source

Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Publishing & Information Services

Publishing & Information Services

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact Cision

  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Careers
  • Accessibility Statement
  • APAC – Simplified Chinese
  • APAC
  • APAC - Traditional Chinese
  • Arabic
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
  • Vietnam

My Services

  • All New Releases
  • Platform

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
[email protected]
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
  • Accessibility
Copyright © 2025 Cision US Inc.